Gusacitinib
Biologicalexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02440685)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 2
- Basal Cell Nevus Syndrome · Phase 2
- Dermatitis, Atopic · Phase 2
- Digital Dermatitis · Phase 2
- Eczema · Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Primary Myelofibrosis · Phase 1/Phase 2
- Skin Neoplasms · Phase 1/Phase 2
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
- Janus Kinase (JAK)INHIBITOR
Janus Kinase (JAK) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1- Mol. weight
- 460.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594275 ↗
Also known as
- asn002
- asn-002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04416516 | Phase 2 | Jul 31, 2020 | Central Brisbane Dermatology, Stamford Pharmaceuticals |
| NCT03728504 | Phase 2 | Jan 3, 2019 | Asana BioSciences |
| NCT03654755 | Phase 2 | Sep 30, 2018 | Asana BioSciences |
| NCT03531957 | Phase 2 | Jul 5, 2018 | Asana BioSciences |
| NCT03208296 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2017 | Oregon Health and Science University, Stamford Pharmaceuticals |
| NCT03139981 | Phase 1 | Apr 12, 2017 | Asana BioSciences |
| NCT02853643 | Phase 1 | Jul 1, 2016 | Asana BioSciences, inVentiv |
| NCT02550678 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Siller Medical T/A Central Brisbane Dermatology, Sinclair Dermatology Pty Ltd, Stamford Pharmaceuticals, Veracity Clinical Research |
| NCT02440685 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | Asana BioSciences |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asana BioSciences | For profit | 6 | 6 | 2 | 2015 |
| Stamford Pharmaceuticals | For profit | 3 | 3 | 1 | 2015 |
| Central Brisbane Dermatology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| inVentiv | For profit | 1 | 0 | 1 | 2016 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Siller Medical T/A Central Brisbane Dermatology | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Sinclair Dermatology Pty Ltd | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Veracity Clinical Research | For profit | 1 | 0 | 1 | 2015 |
8 organizations
Page 1 / 1